However, in terms of curing colorectal cancer (CRC), the majority of patients would present non-response to anti-PD-1 treatment due to the insufficient tumor-infiltrating lymphocytes (TILs) in the tumor microenvironment (TME) (3, 4). Here, PDCD1 is linked to colorectal carcinoma.